English

Sarepta Therapeutics, Inc.

EDGAR

SRPT Quarterly report (10-Q) · filed 2026-08-05

Annual consolidated revenue for 2025: about USD 1.864B, using the latest reported figures. The previous period, 2024, was about USD 1.788B.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

329 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 328689000 USD Source

Operating margin

4.04%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 13291000 USD Source
Revenue: 328689000 USD Source

Operating cash flow

197 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -5613000 USD Source
Operating Cash Flow: -202683000 USD Source

Free cash flow

197 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -5613000 USD Source
Operating Cash Flow: -202683000 USD Source
Capital Expenditure: 2636000 USD Source
Capital Expenditure: 2081000 USD Source

Cash and cash equivalents: 571 million USD 2026-06-30 Source
Exact value

571100000 USD
Long-term debt including current maturities: 848 million USD 2026-06-30 Source
Exact value

847623000 USD
Shares outstanding: 106 million shares 2026-06-30 Source
Exact value

105623500 shares

Reported share-count change

8.10% · 7.92 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

97706074 shares · 2025-06-30· Source
105623500 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.5 billion USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 399356000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 442934000 USD · 2025-10-01 – 2025-12-31 Source
Revenue: 330515000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 328689000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-137 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -50568000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -412226000 USD · 2025-10-01 – 2025-12-31 Source
Net income: 330959000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -4890000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

111 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -336685000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -322100000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -205479000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -336685000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -202683000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -5613000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -202683000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

29.2 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 98381000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 75447000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 101972000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 98381000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2081000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 2636000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 2081000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

81.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -336685000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -322100000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -205479000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -336685000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -202683000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -5613000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -202683000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 98381000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 75447000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 101972000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 98381000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2081000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 2636000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 2081000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-05.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 9 of 11 periods available· newest 2025-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+4.3%

Prior period

USD 1.79 billion

2024-01-01 – 2024-12-31
Current period

USD 1.86 billion

2025-01-01 – 2025-12-31

Exact inputs and evidence

1864296000 − 1787960000 = 76336000 USD

1787960000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1864296000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Sarepta Therapeutics, Inc. · 2025-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Year-over-year change in Revenue: 76336000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1864296000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#5075927 Filing: 000119312526084144 Input fundies:Revenue: 1787960000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#5077709 Filing: 000119312526084144
The citation records this snapshot. The page link may show a newer release later.
Net income
-403.3%

Prior period

USD 235.24 million

2024-01-01 – 2024-12-31
Current period

−USD 713.41 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-713410000 − 235239000 = -948649000 USD

235239000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-713410000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Sarepta Therapeutics, Inc. · 2025-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Year-over-year change in Net income: -948649000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -713410000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#7054417 Filing: 000119312526084144 Input fundies:NetIncome: 235239000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#7056070 Filing: 000119312526084144
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 308,000

Prior period

−USD 205.79 million

2024-01-01 – 2024-12-31
Current period

−USD 205.48 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-205479000 − -205787000 = 308000 USD

-205787000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-205479000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Sarepta Therapeutics, Inc. · 2025-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Year-over-year change in Operating cash flow: 308000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -205479000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4055873 Filing: 000119312526084144 Input fundies:OperatingCashFlow: -205787000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4057757 Filing: 000119312526084144
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-25.5%

Prior period

USD 136.96 million

2024-01-01 – 2024-12-31
Current period

USD 101.97 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

101972000 − 136956000 = -34984000 USD

136956000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
101972000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Sarepta Therapeutics, Inc. · 2025-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Year-over-year change in Capital expenditure: -34984000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 101972000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4085968 Filing: 000119312526084144 Input fundies:CapitalExpenditure: 136956000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4087739 Filing: 000119312526084144
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 1.86 billion 100% of revenue
Operating costs Derived USD 2.56 billion 138% of revenue
Operating income −USD 699.78 million −38% of revenue
Tax, interest and other Derived USD 13.63 million 0.7% of revenue
Net income −USD 713.41 million −38% of revenue

Cash

Operating cash flow −USD 205.48 million −11% of revenue
Capital expenditure USD 101.97 million 5.5% of revenue
Free cash flow Derived −USD 307.45 million −16% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 5,020% of revenue.
2017 Operating loss: operating costs were 211% of revenue.
2018 Operating loss: operating costs were 214% of revenue.
2019 Operating loss: operating costs were 285% of revenue.
2020 Operating loss: operating costs were 224% of revenue.
2021 Operating loss: operating costs were 165% of revenue.
2022 Operating loss: operating costs were 164% of revenue.
2023 Operating loss: operating costs were 123% of revenue.
2024 Net income was higher than operating income, so the split is not drawn.
2025 Operating loss: operating costs were 138% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	5421000	272151000 Derived	-266730000	535000 Derived	-267265000	-251161000 Derived	Source 2016-01-01 – 2016-12-31: 5421000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -266730000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -267265000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -245820000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 5341000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	154584000	326222000 Derived	-171638000	-120950000 Derived	-50688000	-243996000 Derived	Source 2017-01-01 – 2017-12-31: 154584000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -171638000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -50688000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -231996000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 12000000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	301034000	644662000 Derived	-343628000	18290000 Derived	-361918000	-449817000 Derived	Source 2018-01-01 – 2018-12-31: 301034000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -343628000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -361918000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -388660000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 61157000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	380833000	1086396000 Derived	-705563000	9512000 Derived	-715075000	-516094000 Derived	Source 2019-01-01 – 2019-12-31: 380833000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -705563000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -715075000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -456463000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 59631000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	455900000	1020063000 Derived	-564163000	-10035000 Derived	-554128000	25264000 Derived	Source 2020-01-01 – 2020-12-31: 455900000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -564163000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -554128000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 107466000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 82202000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	701887000	1161597000 Derived	-459710000	-40930000 Derived	-418780000	-481662000 Derived	Source 2021-01-01 – 2021-12-31: 701887000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -459710000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -418780000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -443172000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 38490000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	843769000	1379970000 Derived	-536201000	167287000 Derived	-703488000	-356170000 Derived	Source 2022-01-01 – 2022-12-31: 843769000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -536201000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -703488000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -325346000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 30824000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	1144876000	1412700000 Derived	-267824000	268153000 Derived	-535977000	-577099000 Derived	Source 2023-01-01 – 2023-12-31: 1144876000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -267824000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -535977000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -500993000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 76106000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	1787960000	1569879000 Derived	218081000	-17158000 Derived	235239000	-342743000 Derived	Source 2024-01-01 – 2024-12-31: 1787960000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: 218081000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: 235239000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -205787000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 136956000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	1864296000	2564077000 Derived	-699781000	13629000 Derived	-713410000	-307451000 Derived	Source 2025-01-01 – 2025-12-31: 1864296000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -699781000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -713410000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -205479000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 101972000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.9B 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	5421000	Revenue: 5421000 Open source
20172017-12-31	Revenue	154584000	Revenue: 154584000 Open source
20182018-12-31	Revenue	301034000	Revenue: 301034000 Open source
20192019-12-31	Revenue	380833000	Revenue: 380833000 Open source
20202020-12-31	Revenue	455900000	Revenue: 455900000 Open source
20212021-12-31	Revenue	701887000	Revenue: 701887000 Open source
20222022-12-31	Revenue	843769000	Revenue: 843769000 Open source
20232023-12-31	Revenue	1144876000	Revenue: 1144876000 Open source
20242024-12-31	Revenue	1787960000	Revenue: 1787960000 Open source
20252025-12-31	Revenue	1864296000	Revenue: 1864296000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

4.3% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	332.6%	Revenue: 5421000 Open source Revenue: 1253000 Open source
20172017-12-31	Year over year	2,751.6%	Revenue: 154584000 Open source Revenue: 5421000 Open source
20182018-12-31	Year over year	94.7%	Revenue: 301034000 Open source Revenue: 154584000 Open source
20192019-12-31	Year over year	26.5%	Revenue: 380833000 Open source Revenue: 301034000 Open source
20202020-12-31	Year over year	19.7%	Revenue: 455900000 Open source Revenue: 380833000 Open source
20212021-12-31	Year over year	54%	Revenue: 701887000 Open source Revenue: 455900000 Open source
20222022-12-31	Year over year	20.2%	Revenue: 843769000 Open source Revenue: 701887000 Open source
20232023-12-31	Year over year	35.7%	Revenue: 1144876000 Open source Revenue: 843769000 Open source
20242024-12-31	Year over year	56.2%	Revenue: 1787960000 Open source Revenue: 1144876000 Open source
20252025-12-31	Year over year	4.3%	Revenue: 1864296000 Open source Revenue: 1787960000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -37.5% 2025

Net margin -38.3% 2025

Free cash flow margin -16.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-4,920.3%	Operating Income: -266730000 Open source Revenue: 5421000 Open source
20172017-12-31	Operating margin	-111%	Operating Income: -171638000 Open source Revenue: 154584000 Open source
20182018-12-31	Operating margin	-114.1%	Operating Income: -343628000 Open source Revenue: 301034000 Open source
20192019-12-31	Operating margin	-185.3%	Operating Income: -705563000 Open source Revenue: 380833000 Open source
20202020-12-31	Operating margin	-123.7%	Operating Income: -564163000 Open source Revenue: 455900000 Open source
20212021-12-31	Operating margin	-65.5%	Operating Income: -459710000 Open source Revenue: 701887000 Open source
20222022-12-31	Operating margin	-63.5%	Operating Income: -536201000 Open source Revenue: 843769000 Open source
20232023-12-31	Operating margin	-23.4%	Operating Income: -267824000 Open source Revenue: 1144876000 Open source
20242024-12-31	Operating margin	12.2%	Operating Income: 218081000 Open source Revenue: 1787960000 Open source
20252025-12-31	Operating margin	-37.5%	Operating Income: -699781000 Open source Revenue: 1864296000 Open source
20162016-12-31	Net margin	-4,930.2%	Net Income: -267265000 Open source Revenue: 5421000 Open source
20172017-12-31	Net margin	-32.8%	Net Income: -50688000 Open source Revenue: 154584000 Open source
20182018-12-31	Net margin	-120.2%	Net Income: -361918000 Open source Revenue: 301034000 Open source
20192019-12-31	Net margin	-187.8%	Net Income: -715075000 Open source Revenue: 380833000 Open source
20202020-12-31	Net margin	-121.5%	Net Income: -554128000 Open source Revenue: 455900000 Open source
20212021-12-31	Net margin	-59.7%	Net Income: -418780000 Open source Revenue: 701887000 Open source
20222022-12-31	Net margin	-83.4%	Net Income: -703488000 Open source Revenue: 843769000 Open source
20232023-12-31	Net margin	-46.8%	Net Income: -535977000 Open source Revenue: 1144876000 Open source
20242024-12-31	Net margin	13.2%	Net Income: 235239000 Open source Revenue: 1787960000 Open source
20252025-12-31	Net margin	-38.3%	Net Income: -713410000 Open source Revenue: 1864296000 Open source
20162016-12-31	Free cash flow margin	-4,633.1%	Revenue: 5421000 Open source Operating Cash Flow: -245820000 Open source Capital Expenditure: 5341000 Open source
20172017-12-31	Free cash flow margin	-157.8%	Revenue: 154584000 Open source Operating Cash Flow: -231996000 Open source Capital Expenditure: 12000000 Open source
20182018-12-31	Free cash flow margin	-149.4%	Revenue: 301034000 Open source Operating Cash Flow: -388660000 Open source Capital Expenditure: 61157000 Open source
20192019-12-31	Free cash flow margin	-135.5%	Revenue: 380833000 Open source Operating Cash Flow: -456463000 Open source Capital Expenditure: 59631000 Open source
20202020-12-31	Free cash flow margin	5.5%	Revenue: 455900000 Open source Operating Cash Flow: 107466000 Open source Capital Expenditure: 82202000 Open source
20212021-12-31	Free cash flow margin	-68.6%	Revenue: 701887000 Open source Operating Cash Flow: -443172000 Open source Capital Expenditure: 38490000 Open source
20222022-12-31	Free cash flow margin	-42.2%	Revenue: 843769000 Open source Operating Cash Flow: -325346000 Open source Capital Expenditure: 30824000 Open source
20232023-12-31	Free cash flow margin	-50.4%	Revenue: 1144876000 Open source Operating Cash Flow: -500993000 Open source Capital Expenditure: 76106000 Open source
20242024-12-31	Free cash flow margin	-19.2%	Revenue: 1787960000 Open source Operating Cash Flow: -205787000 Open source Capital Expenditure: 136956000 Open source
20252025-12-31	Free cash flow margin	-16.5%	Revenue: 1864296000 Open source Operating Cash Flow: -205479000 Open source Capital Expenditure: 101972000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -205.5M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-245820000	Operating Cash Flow: -245820000 Open source
20172017-12-31	Operating cash flow	-231996000	Operating Cash Flow: -231996000 Open source
20182018-12-31	Operating cash flow	-388660000	Operating Cash Flow: -388660000 Open source
20192019-12-31	Operating cash flow	-456463000	Operating Cash Flow: -456463000 Open source
20202020-12-31	Operating cash flow	107466000	Operating Cash Flow: 107466000 Open source
20212021-12-31	Operating cash flow	-443172000	Operating Cash Flow: -443172000 Open source
20222022-12-31	Operating cash flow	-325346000	Operating Cash Flow: -325346000 Open source
20232023-12-31	Operating cash flow	-500993000	Operating Cash Flow: -500993000 Open source
20242024-12-31	Operating cash flow	-205787000	Operating Cash Flow: -205787000 Open source
20252025-12-31	Operating cash flow	-205479000	Operating Cash Flow: -205479000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -307.5M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-251161000	Operating Cash Flow: -245820000 Open source Capital Expenditure: 5341000 Open source
20172017-12-31	Free cash flow	-243996000	Operating Cash Flow: -231996000 Open source Capital Expenditure: 12000000 Open source
20182018-12-31	Free cash flow	-449817000	Operating Cash Flow: -388660000 Open source Capital Expenditure: 61157000 Open source
20192019-12-31	Free cash flow	-516094000	Operating Cash Flow: -456463000 Open source Capital Expenditure: 59631000 Open source
20202020-12-31	Free cash flow	25264000	Operating Cash Flow: 107466000 Open source Capital Expenditure: 82202000 Open source
20212021-12-31	Free cash flow	-481662000	Operating Cash Flow: -443172000 Open source Capital Expenditure: 38490000 Open source
20222022-12-31	Free cash flow	-356170000	Operating Cash Flow: -325346000 Open source Capital Expenditure: 30824000 Open source
20232023-12-31	Free cash flow	-577099000	Operating Cash Flow: -500993000 Open source Capital Expenditure: 76106000 Open source
20242024-12-31	Free cash flow	-342743000	Operating Cash Flow: -205787000 Open source Capital Expenditure: 136956000 Open source
20252025-12-31	Free cash flow	-307451000	Operating Cash Flow: -205479000 Open source Capital Expenditure: 101972000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

65.9% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	20.6%	Total Liabilities: 87413000 Open source Total Assets: 424104000 Open source
20172017-12-31	Liabilities / assets	39.7%	Total Liabilities: 518747000 Open source Total Assets: 1307964000 Open source
20182018-12-31	Liabilities / assets	37.1%	Total Liabilities: 609799000 Open source Total Assets: 1642075000 Open source
20192019-12-31	Liabilities / assets	55.1%	Total Liabilities: 1004635000 Open source Total Assets: 1822822000 Open source
20202020-12-31	Liabilities / assets	74.5%	Total Liabilities: 2222959000 Open source Total Assets: 2984718000 Open source
20212021-12-31	Liabilities / assets	70.5%	Total Liabilities: 2219965000 Open source Total Assets: 3147974000 Open source
20222022-12-31	Liabilities / assets	87.7%	Total Liabilities: 2743416000 Open source Total Assets: 3128366000 Open source
20232023-12-31	Liabilities / assets	73.7%	Total Liabilities: 2405239000 Open source Total Assets: 3264576000 Open source
20242024-12-31	Liabilities / assets	61.5%	Total Liabilities: 2435431000 Open source Total Assets: 3963173000 Open source
20252025-12-31	Liabilities / assets	65.9%	Total Liabilities: 2209081000 Open source Total Assets: 3349703000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.32× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	4.95×	Current Assets: 373476000 Open source Current Liabilities: 75422000 Open source
20172017-12-31	Current assets / current liabilities	13.91×	Current Assets: 1228644000 Open source Current Liabilities: 88332000 Open source
20182018-12-31	Current assets / current liabilities	8.21×	Current Assets: 1426183000 Open source Current Liabilities: 173690000 Open source
20192019-12-31	Current assets / current liabilities	5.55×	Current Assets: 1468913000 Open source Current Liabilities: 264767000 Open source
20202020-12-31	Current assets / current liabilities	5.97×	Current Assets: 2485196000 Open source Current Liabilities: 416026000 Open source
20212021-12-31	Current assets / current liabilities	5.75×	Current Assets: 2604099000 Open source Current Liabilities: 452733000 Open source
20222022-12-31	Current assets / current liabilities	4.13×	Current Assets: 2557861000 Open source Current Liabilities: 619604000 Open source
20232023-12-31	Current assets / current liabilities	3.95×	Current Assets: 2579331000 Open source Current Liabilities: 653659000 Open source
20242024-12-31	Current assets / current liabilities	4.2×	Current Assets: 3073463000 Open source Current Liabilities: 731684000 Open source
20252025-12-31	Current assets / current liabilities	2.32×	Current Assets: 2537938000 Open source Current Liabilities: 1095290000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 267.27 million Exact value Exact value: -267265000 USD 2016-01-01 – 2016-12-31: -267265000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sarepta Therapeutics, Inc. · 2016-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Net Income: -267265000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -267265000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459019005170/srpt-20181231.xml#231135 Filing: 000156459019005170 The citation records this snapshot. The page link may show a newer release later.	−USD 245.82 million Exact value Exact value: -245820000 USD 2016-01-01 – 2016-12-31: -245820000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sarepta Therapeutics, Inc. · 2016-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Operating Cash Flow: -245820000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -245820000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459019005170/srpt-20181231.xml#264002 Filing: 000156459019005170 The citation records this snapshot. The page link may show a newer release later.	USD 5.34 million Exact value Exact value: 5341000 USD 2016-01-01 – 2016-12-31: 5341000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sarepta Therapeutics, Inc. · 2016-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Capital Expenditure: 5341000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5341000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459019005170/srpt-20181231.xml#264637 Filing: 000156459019005170 The citation records this snapshot. The page link may show a newer release later.	−USD 251.16 million Calculation and evidence -245820000 − 5341000 USD Exact free cash flow: -251161000 USD 2016-01-01 – 2016-12-31: -245820000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 5341000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sarepta Therapeutics, Inc. · 2016-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Free cash flow: -251161000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -245820000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459019005170/srpt-20181231.xml#264002 Filing: 000156459019005170 Input fundies:CapitalExpenditure: 5341000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459019005170/srpt-20181231.xml#264637 Filing: 000156459019005170 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 50.69 million Exact value Exact value: -50688000 USD 2017-01-01 – 2017-12-31: -50688000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sarepta Therapeutics, Inc. · 2017-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Net Income: -50688000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50688000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459020006769/srpt-10k_20191231.htm#5906648 Filing: 000156459020006769 The citation records this snapshot. The page link may show a newer release later.	−USD 232 million Exact value Exact value: -231996000 USD 2017-01-01 – 2017-12-31: -231996000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sarepta Therapeutics, Inc. · 2017-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Operating Cash Flow: -231996000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -231996000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459020006769/srpt-10k_20191231.htm#3567241 Filing: 000156459020006769 The citation records this snapshot. The page link may show a newer release later.	USD 12 million Exact value Exact value: 12000000 USD 2017-01-01 – 2017-12-31: 12000000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sarepta Therapeutics, Inc. · 2017-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Capital Expenditure: 12000000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12000000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459020006769/srpt-10k_20191231.htm#3583567 Filing: 000156459020006769 The citation records this snapshot. The page link may show a newer release later.	−USD 244 million Calculation and evidence -231996000 − 12000000 USD Exact free cash flow: -243996000 USD 2017-01-01 – 2017-12-31: -231996000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 12000000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sarepta Therapeutics, Inc. · 2017-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Free cash flow: -243996000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -231996000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459020006769/srpt-10k_20191231.htm#3567241 Filing: 000156459020006769 Input fundies:CapitalExpenditure: 12000000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459020006769/srpt-10k_20191231.htm#3583567 Filing: 000156459020006769 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 361.92 million Exact value Exact value: -361918000 USD 2018-01-01 – 2018-12-31: -361918000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sarepta Therapeutics, Inc. · 2018-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Net Income: -361918000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -361918000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459021009835/srpt-10k_20201231.htm#6074174 Filing: 000156459021009835 The citation records this snapshot. The page link may show a newer release later.	−USD 388.66 million Exact value Exact value: -388660000 USD 2018-01-01 – 2018-12-31: -388660000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sarepta Therapeutics, Inc. · 2018-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Operating Cash Flow: -388660000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -388660000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459021009835/srpt-10k_20201231.htm#3872009 Filing: 000156459021009835 The citation records this snapshot. The page link may show a newer release later.	USD 61.16 million Exact value Exact value: 61157000 USD 2018-01-01 – 2018-12-31: 61157000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sarepta Therapeutics, Inc. · 2018-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Capital Expenditure: 61157000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 61157000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459021009835/srpt-10k_20201231.htm#3888326 Filing: 000156459021009835 The citation records this snapshot. The page link may show a newer release later.	−USD 449.82 million Calculation and evidence -388660000 − 61157000 USD Exact free cash flow: -449817000 USD 2018-01-01 – 2018-12-31: -388660000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 61157000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sarepta Therapeutics, Inc. · 2018-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Free cash flow: -449817000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -388660000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459021009835/srpt-10k_20201231.htm#3872009 Filing: 000156459021009835 Input fundies:CapitalExpenditure: 61157000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000156459021009835/srpt-10k_20201231.htm#3888326 Filing: 000156459021009835 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 715.08 million Exact value Exact value: -715075000 USD 2019-01-01 – 2019-12-31: -715075000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sarepta Therapeutics, Inc. · 2019-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Net Income: -715075000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -715075000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017022002517/srpt-20211231.htm#6072678 Filing: 000095017022002517 The citation records this snapshot. The page link may show a newer release later.	−USD 456.46 million Exact value Exact value: -456463000 USD 2019-01-01 – 2019-12-31: -456463000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sarepta Therapeutics, Inc. · 2019-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Operating Cash Flow: -456463000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -456463000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017022002517/srpt-20211231.htm#3855807 Filing: 000095017022002517 The citation records this snapshot. The page link may show a newer release later.	USD 59.63 million Exact value Exact value: 59631000 USD 2019-01-01 – 2019-12-31: 59631000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sarepta Therapeutics, Inc. · 2019-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Capital Expenditure: 59631000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 59631000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017022002517/srpt-20211231.htm#3869935 Filing: 000095017022002517 The citation records this snapshot. The page link may show a newer release later.	−USD 516.09 million Calculation and evidence -456463000 − 59631000 USD Exact free cash flow: -516094000 USD 2019-01-01 – 2019-12-31: -456463000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 59631000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sarepta Therapeutics, Inc. · 2019-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Free cash flow: -516094000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -456463000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017022002517/srpt-20211231.htm#3855807 Filing: 000095017022002517 Input fundies:CapitalExpenditure: 59631000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017022002517/srpt-20211231.htm#3869935 Filing: 000095017022002517 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 554.13 million Exact value Exact value: -554128000 USD 2020-01-01 – 2020-12-31: -554128000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sarepta Therapeutics, Inc. · 2020-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Net Income: -554128000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -554128000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017023005062/srpt-20221231.htm#6785185 Filing: 000095017023005062 The citation records this snapshot. The page link may show a newer release later.	USD 107.47 million Exact value Exact value: 107466000 USD 2020-01-01 – 2020-12-31: 107466000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sarepta Therapeutics, Inc. · 2020-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Operating Cash Flow: 107466000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 107466000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017023005062/srpt-20221231.htm#4249481 Filing: 000095017023005062 The citation records this snapshot. The page link may show a newer release later.	USD 82.2 million Exact value Exact value: 82202000 USD 2020-01-01 – 2020-12-31: 82202000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sarepta Therapeutics, Inc. · 2020-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Capital Expenditure: 82202000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 82202000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017023005062/srpt-20221231.htm#4265126 Filing: 000095017023005062 The citation records this snapshot. The page link may show a newer release later.	USD 25.26 million Calculation and evidence 107466000 − 82202000 USD Exact free cash flow: 25264000 USD 2020-01-01 – 2020-12-31: 107466000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 82202000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sarepta Therapeutics, Inc. · 2020-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Free cash flow: 25264000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 107466000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017023005062/srpt-20221231.htm#4249481 Filing: 000095017023005062 Input fundies:CapitalExpenditure: 82202000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017023005062/srpt-20221231.htm#4265126 Filing: 000095017023005062 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 418.78 million Exact value Exact value: -418780000 USD 2021-01-01 – 2021-12-31: -418780000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sarepta Therapeutics, Inc. · 2021-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Net Income: -418780000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -418780000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017024022036/srpt-20231231.htm#4934045 Filing: 000095017024022036 The citation records this snapshot. The page link may show a newer release later.	−USD 443.17 million Exact value Exact value: -443172000 USD 2021-01-01 – 2021-12-31: -443172000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sarepta Therapeutics, Inc. · 2021-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Operating Cash Flow: -443172000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -443172000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017024022036/srpt-20231231.htm#3108626 Filing: 000095017024022036 The citation records this snapshot. The page link may show a newer release later.	USD 38.49 million Exact value Exact value: 38490000 USD 2021-01-01 – 2021-12-31: 38490000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sarepta Therapeutics, Inc. · 2021-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Capital Expenditure: 38490000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 38490000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017024022036/srpt-20231231.htm#3122542 Filing: 000095017024022036 The citation records this snapshot. The page link may show a newer release later.	−USD 481.66 million Calculation and evidence -443172000 − 38490000 USD Exact free cash flow: -481662000 USD 2021-01-01 – 2021-12-31: -443172000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 38490000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sarepta Therapeutics, Inc. · 2021-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Free cash flow: -481662000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -443172000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017024022036/srpt-20231231.htm#3108626 Filing: 000095017024022036 Input fundies:CapitalExpenditure: 38490000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017024022036/srpt-20231231.htm#3122542 Filing: 000095017024022036 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 703.49 million Exact value Exact value: -703488000 USD 2022-01-01 – 2022-12-31: -703488000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sarepta Therapeutics, Inc. · 2022-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Net Income: -703488000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -703488000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017025029973/srpt-20241231.htm#5924725 Filing: 000095017025029973 The citation records this snapshot. The page link may show a newer release later.	−USD 325.35 million Exact value Exact value: -325346000 USD 2022-01-01 – 2022-12-31: -325346000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sarepta Therapeutics, Inc. · 2022-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Operating Cash Flow: -325346000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -325346000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017025029973/srpt-20241231.htm#3536719 Filing: 000095017025029973 The citation records this snapshot. The page link may show a newer release later.	USD 30.82 million Exact value Exact value: 30824000 USD 2022-01-01 – 2022-12-31: 30824000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sarepta Therapeutics, Inc. · 2022-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Capital Expenditure: 30824000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 30824000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017025029973/srpt-20241231.htm#3548975 Filing: 000095017025029973 The citation records this snapshot. The page link may show a newer release later.	−USD 356.17 million Calculation and evidence -325346000 − 30824000 USD Exact free cash flow: -356170000 USD 2022-01-01 – 2022-12-31: -325346000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 30824000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sarepta Therapeutics, Inc. · 2022-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Free cash flow: -356170000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -325346000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017025029973/srpt-20241231.htm#3536719 Filing: 000095017025029973 Input fundies:CapitalExpenditure: 30824000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000095017025029973/srpt-20241231.htm#3548975 Filing: 000095017025029973 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 535.98 million Exact value Exact value: -535977000 USD 2023-01-01 – 2023-12-31: -535977000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sarepta Therapeutics, Inc. · 2023-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Net Income: -535977000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -535977000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#7057803 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.	−USD 500.99 million Exact value Exact value: -500993000 USD 2023-01-01 – 2023-12-31: -500993000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sarepta Therapeutics, Inc. · 2023-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Operating Cash Flow: -500993000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -500993000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4059641 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.	USD 76.11 million Exact value Exact value: 76106000 USD 2023-01-01 – 2023-12-31: 76106000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sarepta Therapeutics, Inc. · 2023-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Capital Expenditure: 76106000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 76106000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4089510 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.	−USD 577.1 million Calculation and evidence -500993000 − 76106000 USD Exact free cash flow: -577099000 USD 2023-01-01 – 2023-12-31: -500993000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 76106000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sarepta Therapeutics, Inc. · 2023-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Free cash flow: -577099000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -500993000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4059641 Filing: 000119312526084144 Input fundies:CapitalExpenditure: 76106000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4089510 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	USD 235.24 million Exact value Exact value: 235239000 USD 2024-01-01 – 2024-12-31: 235239000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sarepta Therapeutics, Inc. · 2024-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Net Income: 235239000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: 235239000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#7056070 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.	−USD 205.79 million Exact value Exact value: -205787000 USD 2024-01-01 – 2024-12-31: -205787000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sarepta Therapeutics, Inc. · 2024-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Operating Cash Flow: -205787000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -205787000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4057757 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.	USD 136.96 million Exact value Exact value: 136956000 USD 2024-01-01 – 2024-12-31: 136956000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sarepta Therapeutics, Inc. · 2024-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Capital Expenditure: 136956000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 136956000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4087739 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.	−USD 342.74 million Calculation and evidence -205787000 − 136956000 USD Exact free cash flow: -342743000 USD 2024-01-01 – 2024-12-31: -205787000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 136956000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sarepta Therapeutics, Inc. · 2024-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Free cash flow: -342743000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -205787000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4057757 Filing: 000119312526084144 Input fundies:CapitalExpenditure: 136956000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4087739 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 713.41 million Exact value Exact value: -713410000 USD 2025-01-01 – 2025-12-31: -713410000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sarepta Therapeutics, Inc. · 2025-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Net Income: -713410000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -713410000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#7054417 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.	−USD 205.48 million Exact value Exact value: -205479000 USD 2025-01-01 – 2025-12-31: -205479000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sarepta Therapeutics, Inc. · 2025-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Operating Cash Flow: -205479000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -205479000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4055873 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.	USD 101.97 million Exact value Exact value: 101972000 USD 2025-01-01 – 2025-12-31: 101972000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sarepta Therapeutics, Inc. · 2025-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Capital Expenditure: 101972000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 101972000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4085968 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.	−USD 307.45 million Calculation and evidence -205479000 − 101972000 USD Exact free cash flow: -307451000 USD 2025-01-01 – 2025-12-31: -205479000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 101972000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sarepta Therapeutics, Inc. · 2025-12-31 Sarepta Therapeutics, Inc. (edgar:873303) Free cash flow: -307451000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:37:08Z Snapshot: 0eb3df83c91ac0ef100444aa704f013946d2bfb64e92bc3243d044aafd960b54 Dimensions: Consolidated View: https://fundies.io/companies/edgar/873303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -205479000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4055873 Filing: 000119312526084144 Input fundies:CapitalExpenditure: 101972000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm#4085968 Filing: 000119312526084144 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

158 filings · 4,986 latest values · 4,986 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000873303, 873303, SRPT, edgar:873303

Also known as ANTIVIRALS INC, AVI BIOPHARMA INC, SAREPTA THERAPEUTICS, INC., Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation